1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. California >
  6. Accord BioPharma Acquires Udenyca

M&A Deal Summary

Accord BioPharma Acquires Udenyca

On April 14, 2025, Accord BioPharma acquired life science company Udenyca from Coherus Biosciences

Acquisition Highlights
  • This is Accord BioPharma’s 1st transaction in the Life Science sector.
  • This is Accord BioPharma’s 1st transaction in the United States.
  • This is Accord BioPharma’s 1st transaction in California.

M&A Deal Summary
Date 2025-04-14
Target Udenyca
Sector Life Science
Buyer(s) Accord BioPharma
Sellers(s) Coherus Biosciences
Deal Type Divestiture

Target

Udenyca

Redwood City, California, United States
Udenyca (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. It increases survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Accord BioPharma

Raleigh, North Carolina, United States
Category Company
Sector Life Science
DESCRIPTION

Accord BioPharma provides accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, the company goes beyond the biology of medicine to see disease from the patients' perspective and develop high-quality therapies that impact patients' lives. Accord BioPharma is based in Raleigh, North Carolina.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2025 M&A 1 of 1

Seller(S) 1

SELLER

Coherus Biosciences

Redwood City, California, United States
Category Company
Founded 2010
Sector Life Science
Employees228
Revenue 267M USD (2024)
DESCRIPTION

Coherus Biosciences is a biotechnology company focused on developing products. Coherus BioSciences was founded in 2010 and is based in Redwood City, California.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Divestiture M&A Deals 2 of 2
State: California M&A 2 of 2
Country: United States M&A 2 of 2
Year: 2025 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-04 Cimerli

Redwood City, California, United States

Cimerli is a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Myopic Choroidal Neovascularization (mCNV). Cimerli is based in Redwood City, California.

Sell $170M
Mergr

Solution for

Product

Company

Legal